view lower estim price target slightli reflect
continu suspens product pharmedium memphi
facil expect issu temporari delay resum
product impact result
pharmedium updat amerisourc today provid updat
pharmedium memphi facil product facil remain
suspend compani remain discuss fda
remedi measur earn call februari
manag expect product resum compani
march product ramp fiscal year reach full
product end fy
financi impact previous estim pharmedium
issu would impact oper profit
ep larg impact estim larger
impact back half lower ep estim
reflect addit oper profit impact second half
larg impact manag expect provid updat
guidanc financi impact earn call may
maintain sector perform maintain sector perform rate
share lower price target ep estim
reduc price target share equal
ep estim
valu usd unless otherwis note
price prior trade day market close estimate unless otherwis note
believ share like multipl rang bound
investor get visibl gener drug price
bottom oper earn growth resum
pressur last
month multipl issu relat drug price
weigh result expect backdrop
improv next month howev believ
best-posit wholesal
meet earn target given conserv guidanc
relationship walgreen though note
rel strength seem reflect current share
estim gener profit
core us drug distribut busi sale gener
drug past two year seen
price gener drug deflat high-single-digit mid-
teen percentag rate profit dollar contribut
fall slightli lower rate gener deflat continu
high-single-digit pace higher believ
volum growth abl
grow earn segment though may best
posit creat spread price fall
upsid risk sector perform rate share
includ stabil drug price environ
could caus earn estim stabil like drive
multipl expans close market multipl
downsid risk sector perform rate includ
acceler drug price deterior gener
market potenti client loss wholesal
sell-sid price compress larger pharmaci
custom gpo
bloomberg capit market estim upside/downside/target
price target share equal
ep estim use multipl reflect
averag forward trade multipl share
upsid scenario share base
ep estim higher base case price-to-earnings
multipl appli ep scenario upsid scenario
ep better ep growth could
driven success partnership walgreen increas
volum across brand gener drug success capit
deploy level gener price deflat
forward multipl repres high end
normal trade rang drug wholes space
multipl like get neg
downsid scenario share base
ep estim base case price-to-earnings multipl
appli ep scenario downsid scenario
ep lower-than-expect ep could
driven worse-than-expect price environ
lower-than-expect brand gener volum lack
avail opportun forward multipl
like get posit share
price target share support sector perform rate equal
ep estim use multipl reflect averag
forward trade multipl share
risk rate price target
forese upsid downsid risk sector perform rate share
upsid risk includ stabil drug price environ could caus earn
estim stabil like drive multipl expans close market multipl
downsid risk includ acceler drug price deterior gener market
potenti client loss wholesal sell-sid price compress
larger pharmaci custom gpo
pharmaceut distribut consult compani oper
distribut segment
distribut segment includ amerisourcebergen drug corpor abdc
compani amerisourcebergen consult servic abc world courier mwi
veterinari suppli busi partnership walgreen boot
allianc global drug sourc distribut product locat
good sold
segment revenu
segment revenu
amort intang
revenu
segment revenu
segment revenu
incom discontinu oper net tax
adjust non-gaap incom continu oper
earn per share continu oper
weight average number share
